GlassScriptPhysician profile
Vincent J Digiovanni
NPI 1497789135
$3,854.90
in general payments reported to CMS, 2019-2025
23 companies · $44.00 in 2025
The $44.00 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,137 · 2020: $651 · 2022: $22.53 · 2025: $44.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,049.57 | 2019-2020 | |
| Biogen, INC. | $565.64 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $394.54 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $328.70 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $223.93 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $199.99 | 2019-2020 | |
| Eisai INC. | $196.33 | 2019-2020 | |
| Amgen INC. | $180.03 | 2019-2020 | |
| Boston Scientific Corporation | $178.19 | 2019-2025 | General - Vascular Intervention, Seismiq Prime Catheter_pi |
| Genzyme Corporation | $95.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $91.59 | 2019 | |
| Lilly USA, LLC | $79.37 | 2019 | |
| Neurelis, INC. | $76.68 | 2020 | |
| Emd Serono, INC. | $37.04 | 2019-2020 | |
| Allergan, INC. | $34.00 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.25 | 2020 | |
| Collegium Pharmaceutical, INC. | $19.00 | 2020 | |
| Acadia Pharmaceuticals INC | $16.27 | 2019 | |
| Ucb, INC. | $15.50 | 2019 | |
| Neurocrine Biosciences, INC. | $14.09 | 2019 | |
| Livanova USA, INC. | $12.99 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.39 | 2019 | |
| Medtronic Vascular, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Digiovanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.